| Drug General Information |
| Drug ID |
D07QXO
|
| Former ID |
DCL000836
|
| Drug Name |
HMR-2934
|
| Drug Type |
Small molecular drug
|
| Indication |
Schizophrenia [ICD9: 295; ICD10:F20]
|
Terminated |
[1]
|
|---|
| Company |
Sanofi-Aventis
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C24H29N7O2
|
| Canonical SMILES |
CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCC<br />C5)C(=O)C
|
| InChI |
1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)
|
| InChIKey |
AHJRHEGDXFFMBM-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
8035907, 11062094, 11538604, 12015755, 14808444, 17137183, 39302900, 46394060, 57361299, 78833389, 99436913, 103461613, 103905660, 103905661, 113915142, 121280258, 124360805, 124757012, 125164718, 126580155, 126671645, 126737419, 131480762, 134339015, 134339302, 134339471, 134964422, 135262045, 135686212, 135686213, 135686228, 135686229, 136367313, 136367838, 136920362, 137184856, 137275973, 141483504, 143498887, 144116345, 152240013, 152258827, 152344089, 160647678, 162202562, 164045126, 172232465, 172919351, 177748911, 178103952
|
| Target and Pathway |
| Target(s) |
D(4) dopamine receptor |
Target Info |
Antagonist |
[1]
|
|---|
| 5-hydroxytryptamine receptor |
Target Info |
Antagonist |
[1]
|
| D(2) dopamine receptor |
Target Info |
Antagonist |
[1]
|
|
KEGG Pathway
|
Neuroactive ligand-receptor interaction
|
|
Dopaminergic synapsehsa04015:Rap1 signaling pathway
|
|
cAMP signaling pathway
|
|
Gap junction
|
|
Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Alcoholism
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Dopamine receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Nicotine pharmacodynamics pathway
|
|
Reactome
|
Dopamine receptors
|
|
G alpha (i) signalling eventsR-HSA-390651:Dopamine receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
Hypothetical Network for Drug Addiction
|
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
Nicotine Activity on Dopaminergic Neurons
|
|
GPCRs, OtherWP666:Hypothetical Network for Drug Addiction
|
| References |
| REF 1 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. Epub 2007 Jul 31. |
|---|
